REG - AstraZeneca PLC - Result of General Meeting

AstraZenecaAnnouncement

Mon 16:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251103:nRSC9795Fa&default-theme=true

RNS Number : 9795F  AstraZeneca PLC  03 November 2025

 

3 November 2025

Result of General Meeting held on 3 November 2025

AstraZeneca PLC (the 'Company') announced that at the General Meeting ('GM')
of shareholders held earlier today, shareholders approved the resolution to
adopt new articles of association of the Company, as required to proceed with
the harmonisation of the Company's equity listing structure. As proposed in
the Circular and Notice of GM circulated on 29 September 2025, the Resolution
was decided by poll vote and was passed as a special resolution.

 

                                                                             Votes for      % of votes cast  Votes against  % of votes cast  Votes cast in total  Total votes cast as a % of issued share capital  Votes withheld
 To adopt new articles of association of the Company in connection with the  1,222,275,967  99.36            7,861,875      0.64             1,230,137,842        79.33                                            2,628,613
 harmonisation of its equity listing structure

Michel Demaré, Chair AstraZeneca said: "Today's significant vote in favour of
the Board's proposal demonstrates strong shareholder support for AstraZeneca's
harmonised listing structure in London, Stockholm and New York.  As the
Company continues to expand and invest in our growing markets, our new
structure will offer the flexibility to access the broadest available pool of
capital, including in the US, enabling more shareholders to participate in
AstraZeneca's exciting future."

 
Next steps and timetable

The expected timetable of principal events as set out in the Circular and
Notice of GM remains unchanged and is replicated below. The following dates
and times are indicative only and are subject to change. If any of the dates
set out in the timetable change, the Company will give notice of this change
by issuing an announcement through a Regulatory News Service.

 Expected date for termination of ADR Programme, delisting of AstraZeneca ADSs   2 February 2026
 and cancellation of the listing and trading of AstraZeneca US Bonds on Nasdaq

 Expected time and date for commencement of trading in AstraZeneca Shares and    By 8:00 a.m. (ET) on 2 February 2026
 AstraZeneca US Bonds on the NYSE
 Expected date for the issuance of AstraZeneca DIs to relevant CREST             On or around 2 February 2026
 participant accounts
 Expected date for the issuance of statements of entitlement for existing CSN    By no later than 16 February 2026
 Eligible Certificated Shareholders and CSN Participants

A copy of the special resolution passed at the GM has been submitted to the
National Storage Mechanism for publication, and will shortly be available for
inspection at (https://data.fca.org.uk/#/nsm/nationalstoragemechanism)
https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism) .

Issued capital

As at 30 October 2025, the number of issued shares of the Company was
1,550,712,906 ordinary shares, which was the total number of shares entitling
the holders to attend and vote for or against the Resolution. In accordance
with the Company's Articles of Association, on a poll every member present in
person or by proxy has one vote for every share held.

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development, and commercialisation of
prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are
sold in more than 125 countries and used by millions of patients worldwide.
Please visit www.astrazeneca.com (http://www.astrazeneca.com/) and follow the
Company on social media @AstraZeneca
(https://www.linkedin.com/company/astrazeneca) .

Contacts

For details on how to contact the Investor Relations Team, please click here
(https://www.astrazeneca.com/investor-relations.html#Contacts) . For Media
contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html)
.

 

Matthew Bowden

Company Secretary

AstraZeneca PLC

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ROMBJBATMTJMBPA



            Copyright 2019 Regulatory News Service, all rights reserved